Vienna, Austria

ESTRO 2023

Session Item

Poster (Digital)
Hypofractionated post-prostatectomy radiotherapy in 16 fractions: a single institution outcome
Pavol Dubinsky, Slovakia


Hypofractionated post-prostatectomy radiotherapy in 16 fractions: a single institution outcome

Pavol Dubinsky1, Katarina Belanova1, Natalia Janickova1, Vladimir Vojtek1, Noemi Balazova1, Zuzana Tomkova1

1East Slovakia Institute of Oncology, Radiation Oncology, Kosice, Slovakia

Show Affiliations
Purpose or Objective

To evaluate treatment outcomes and toxicity of the moderately hypofractionated schedule with the total dose of 52.8 Gy in 16 daily fractions delivered with IMRT/VMAT. The treatment schedule selection was motivated by limited technology resources.

Material and Methods

One hundred consecutive M0 patients with post-prostatectomy radiotherapy were evaluated based on intention to treat. Median age was 64 years. Radiotherapy indication was adjuvant in 19%, early salvage in 46% and salvage (PSA >0,5 ng/ml) in 35%. Clinical target volume was limited to the prostate bed (PB) in 89% and in 11% pelvic nodes irradiation was included. The dose prescription for PTV_PB was 52.8 Gy in 16 fractions of 3.3 Gy and 40 Gy in 16 fractions of 2.5 Gy for PTV_pelvis and treatment was delivered daily by image-guided step-and-shoot IMRT or VMAT. No androgen deprivation treatment (ADT) was administered in 42%, short-term LHRHa in 30%, 2-years bicalutamide in 12% and long-term LHRHa in 16%. Patients were followed with PSA every 3 to 6 months. If indicated, conventional imaging was used before radiotherapy and at PSA progression. The Common Terminology Criteria v.4 for Adverse Events scale was used for toxicity evaluation.


The median follow-up was 61 months. Five-year freedom from biochemical failure (FFBF) was 79.7%, distant metastases-free survival was 93.8% and overall survival was 98.8%.  The multivariate analysis showed the treatment indication was the only significant factor for 5-year FFBF which was 86.3% vs. 67.6% for adjuvant and early salvage vs. salvage radiotherapy respectively (HR 0.15, 95% CI 0.05 – 0.47, p = 0.001). Acute GI toxicity grade 2 was recorded in 24% (mostly rectal mucositis and rectal pain), grade G3 in 2% (one small intestine obstruction after completion of adjuvant radiotherapy and one diarrhea) and acute GU toxicity grade 2 in v 10% (mostly cystitis and urinary frequency) and no grade 3. Cumulative rate of late GI toxicity grade ≥2 was observed in 9% (rectal hemorrhage and fecal incontinence) and late GU toxicity grade ≥2 in 16% (urinary retention, urinary frequency, and progression of urinary incontinence). Metachronous malignancies were recorded in 6% (2 NMIBC, 2 colon cancers, 1 lung cancer and 1 pancreatic cancer).


Observed results confirmed efficacy and safety of post-prostatectomy hypofractionated radiotherapy in 16 daily fractions. Adjuvant and early salvage radiotherapy indication was an independent predictor of favorable long-term biochemical control.